Copenhagen - Delayed Quote DKK

Novo Nordisk A/S (NOVO-B.CO)

444.30

+15.40

+(3.59%)

At close: May 9 at 4:59:51 PM GMT+2

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.

Zacks yesterday

NVO

AZN

JAZZ
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the

GlobeNewswire yesterday

NONOF

NVO
Superb Quarterly Report Opens Door to $100 Price Target on Hims & Hers Health Stock (HIMS)

Hims & Hers Health (HIMS) is outperforming and posting numbers that make you wonder why anyone still doubts the stock’s longevity. Bears have long scoffed at its telehealth model, hammering the stock down to $25 just last month. Yet yesterday’s Q1 results were a masterclass in defiance, with eye-popping revenue and profit growth that sent shorts scrambling. Stock bears are still hanging on, but given how cheap the stock has become, a run towards $100 per share may be coming sooner than most expe

TipRanks yesterday

HIMS

NONOF

NVO
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.

Fortune yesterday

NVO
Novo Nordisk (NVO) Upgraded to Buy: Here's What You Should Know

Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 days ago

NVO
Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Zacks 2 days ago

NVO
Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?

The consensus price target hints at a 51.2% upside potential for Novo Nordisk (NVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 2 days ago

NVO
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?

Several factors have contributed to Lilly's share price decline, including earnings misses and increased competition. For a while, it seemed as if Eli Lilly (NYSE: LLY) could do no wrong. Along the way, Lilly became the largest healthcare company in the world based on market cap.

Motley Fool 2 days ago

LLY

NVO
Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges

Novo Nordisk AS (NVO) reports strong sales and profit growth, while addressing compounding challenges and expanding its market presence.

GuruFocus.com 2 days ago

NVO
These Stocks Moved the Most Today: Alphabet, Nvidia, Super Micro, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More

Alphabet stock tumbles on fears AI search providers could one day replace traditional search engines like Google, Super Micro Computer’s guidance for its fiscal fourth quarter misses analysts’ estimates, and Walt Disney stock surges following an earnings beat.

Barrons.com 3 days ago

SMCI

RIVN

AMD
Novo Nordisk Blames Compounders As It Cuts 2025 Forecast. But Shares Jump.

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of GLP-1 medicines.

Investor's Business Daily 3 days ago

NONOF

NVO
Stock market today: Dow, S&P 500, Nasdaq rise as Fed holds rates steady, Powell sticks to 'wait and see'

Eyes are on what the Fed flags about the economy and rates amid tariffs and Trump pressure.

Yahoo Finance 3 days ago

DIS

^GSPC

NONOF
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy.

FastCompany 3 days ago

NVO
3 major takeaways from Novo Nordisk's Q1 earnings

Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations Yahoo Finance senior health reporter Anjalee Khemlani joins the Catlaysts team to share the biggest takeaways from the pharmaceutical giant's earnings, including its global position in the GLP-1 weight-loss drug space and its partnership with CVS Health (CVS). Catch Anjalee Khemlani's full interview with Novo Nordisk CEO Lars Jørgensen. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Yahoo Finance Video 3 days ago

CVS

NONOF

NVO
Why Novo Nordisk missed its sales estimates on weight-loss drug Wegovy: CEO

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Yahoo Finance 2 days ago

NONOF

NVO

LLY
Novo Nordisk Tops Quarterly Views, Tempers Full-Year Outlook

Novo Nordisk's (NVO) first-quarter results topped Wall Street's projections, while the Danish drugma

PREMIUM
MT Newswires 3 days ago

NVO
Why Novo Nordisk Stock Popped After Earnings

Buying Novo Nordisk stock looks like the cheapest way to invest in GLP-1 drugs.

Motley Fool 3 days ago

NVO
Novo Nordisk CEO on earnings, GLP-1 deal with CVS, manufacturing

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures came out to a total of $11.9 billion, falling in line with Wall Street estimates. Novo Nordisk CEO Lars Jørgensen sits down for an interview with Yahoo Finance senior health reporter Anjalee Khemlani, where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's partnership and price goals with CVS Health (CVS), and the company's outlook on its US manufacturing position and President Trump's proposed pharmaceutical tariffs. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Yahoo Finance Video 3 days ago

CVS

NONOF

NVO
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up

NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.

Zacks 3 days ago

NVO

LLY
Novo Nordisk Stock Jumps After Earnings. Compounding Market’s Growth Took it By Surprise

The Danish drugmaker now expects sales growth between 13% and 21%, down from a previous range of 16% to 24%.

Barrons.com 3 days ago

NVO

LLY

Performance Overview

Return	NOVO-B.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	-27.63%	-3.84%
1-Year	-48.66%	-11.55%
3-Year	+23.06%	+2.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOVO-B.CO)

Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Superb Quarterly Report Opens Door to $100 Price Target on Hims & Hers Health Stock (HIMS)

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk (NVO) Upgraded to Buy: Here's What You Should Know

Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?

Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?

Down Nearly 20%: Should You Buy the Dip on Eli Lilly?

Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges

These Stocks Moved the Most Today: Alphabet, Nvidia, Super Micro, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More

Novo Nordisk Blames Compounders As It Cuts 2025 Forecast. But Shares Jump.

Stock market today: Dow, S&P 500, Nasdaq rise as Fed holds rates steady, Powell sticks to 'wait and see'

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

3 major takeaways from Novo Nordisk's Q1 earnings

Why Novo Nordisk missed its sales estimates on weight-loss drug Wegovy: CEO

Novo Nordisk Tops Quarterly Views, Tempers Full-Year Outlook

Why Novo Nordisk Stock Popped After Earnings

Novo Nordisk CEO on earnings, GLP-1 deal with CVS, manufacturing

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up

Novo Nordisk Stock Jumps After Earnings. Compounding Market’s Growth Took it By Surprise

Performance Overview